TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05751421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution
Description: zynrelef will be administered during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: adductor canal block will be performed using bupivacaine before surgery
Study: NCT04191811

Intervention type: BEHAVIORAL
Intervention: Internet-delivered cognitive behavioral therapy for major depressive disorder
Description: Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.

Intervention type: BEHAVIORAL
Intervention: Internet-delivered cognitive behavioral therapy for insomnia
Description: Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.

Intervention type: BEHAVIORAL
Intervention: Internet-delivered cognitive behavioral therapy for social anxiety disorder
Description: Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
Study: NCT06368388

Intervention type: OTHER
Intervention: Prospective data collection
Description: Prospective data collection prior to, during and after phage treatment.
Study: NCT05751421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary total knee replacement
Description: primary total knee replacement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary total knee replacement
Description: primary total knee replacement
Study: NCT05416840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine controlled-release patch
Description: Enrolled patients receive clonidine patch (2.5 mg), once a week. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Enrolled patients receive amlodipine (5 mg), once daily. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6).
Study: NCT05107947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biocentric light
Description: Light that changes in intensity and spectral distribution during the day to mimick daylight. High in intensity and high circadian stimulus during daytime and low intensity and low circadian stimulus during late afternoon and night.
Study: NCT05085444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Assigned Interventions CD19/BCMA CAR T-cells
Description: Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
Study: NCT04748731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet mentalization-based video feedback intervention to improve parental sensitivity in mother-infant dyads with maternal depressive symptoms
Description: a weekly online brief intervention using video-feedback and psycho-educational materials on early parenting

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psycho-Educational Intervention
Description: Reception of psycho-educational materials
Study: NCT04799821

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will be asked to refrain from walnut intake and to follow an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut intake
Description: Participants will be asked to consume walnuts along with an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
Study: NCT06098976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water Jet
Description: The water jet works by directing a stream of water towards the gap between your teeth. The stream of water helps to loosen and remove plaque and food particles stuck in this area.
Study: NCT05659173

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood taking
Description: Blood test for vitamin D level and DNA extraction for VDR gene polymorphism

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood taking
Description: Blood test for vitamin D level and DNA extraction for VDR gene polymorphism
Study: NCT06207539

Intervention type: DRUG
Group type: OTHER
Intervention: hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company
Description: compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.

Intervention type: DRUG
Group type: OTHER
Intervention: misoprostol under the generic name of misotac tablets
Description: compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.

Intervention type: DRUG
Group type: OTHER
Intervention: misoprostol under the generic name of misotac tablets
Description: compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
Study: NCT04995016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor，Pembrolizumab 200mg IV, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
Study: NCT05102929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active intermittent Theta Burst Stimulation (iTBS)
Description: iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with patients with schizophrenia. This research study is using iTBS off label in SCZ patients to examine research questions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active intermittent Theta Burst Stimulation (iTBS)
Description: iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with patients with schizophrenia. This research study is using iTBS off label in SCZ patients to examine research questions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham intermittent Theta Burst Stimulation (iTBS)
Description: Sham TBS over the left DLPFC will be performed using a Cool-B65 A/P TMS coil, designed to support blinded clinical trials. Specifically, when the coil is placed in the P position (i.e. the placebo position), only a very small amount of current is induced in tissue, thus preventing the activation of cortical neurons.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham intermittent Theta Burst Stimulation (iTBS)
Description: Sham TBS over the left DLPFC will be performed using a Cool-B65 A/P TMS coil, designed to support blinded clinical trials. Specifically, when the coil is placed in the P position (i.e. the placebo position), only a very small amount of current is induced in tissue, thus preventing the activation of cortical neurons.
Study: NCT05680584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 3 MG
Description: 0.1 mg/ kg melatonin in 10 ml apple juice 1 hour before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyzine Pill
Description: 1 mg/ kg hydroxyzine in 10 ml apple juice 1 hour before induction of anesthesia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml apple juice 1 hour before induction of anesthesia
Study: NCT06368388

Intervention type: OTHER
Intervention: Prospective data collection
Description: Prospective data collection prior to, during and after standard infection treatment.
Study: NCT05873296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: The intervention will last for 12 weeks, a health education program (face-to-face meetings and information in social networks).
Study: NCT05509881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: Patients in the CGM arm will undergo continuous real-time unblinded CGM using Dexcom CGM devices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (Self-monitored blood glucose)
Description: Patients in the usual care arm will conduct self-monitored blood glucose at least 4 times/day.
Study: NCT06398015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction of hip abductor tendon tear
Description: If the patient is allocated to surgical reconstruction, the incision from the sham surgery is continued into the iliotibial band (ITB) and down to the hip abductor tendon complex/greater trochanter. A standardized reconstruction of the HAT with bone anchors is then performed.~This standardized procedure has been used by the surgeons for the last 6 years. The ITB is then closed with looped suture, the subcutaneous tissue sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing is applied.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham surgery of hip abductor tendon tear
Description: If the patient is allocated to sham surgery, the incision will only include the skin and subcutaneous tissue. Subsequently, the subcutaneous tissue will be sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing applied. The patient will be kept in general anesthesia for 10 minutes after the procedure is finalized to mimic a true intervention (to hinder staff or relatives to comment on the duration of the procedure). The normal standard procedure takes approximately 40 minutes.
Study: NCT05886205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iPSC-Exos
Description: iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
Study: NCT05469334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DeStress for Health Program Participants
Description: Behavioral: DeStress for Health Program The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals, with an additional class five as a check in that will be used for survey completion. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
Study: NCT05355870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training Intervention
Description: Participants in the intervention group will complete a series of cognitive training exercises adapted from the BrainHQ. Results from the intervention development activities will be used to finalize the dose, frequency, and duration of the training. Each session will include 2 training exercises that target different cognitive domains. As participants progress, the difficulty level will be automatically adapted based on participants' performance.
Study: NCT05662579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: There will be 2 reevaluations of the participants, similar to the initial: at the end of the exercise protocol and in a follow-up of 12 weeks after the end of the protocol.~The contraction phase of each exercise will be 2 concentric seconds, 1 isometric second and 2 eccentric seconds, followed by 1 second of rest; there will be approximately 90 seconds of rest between each set of 10 repetitions, time the other member will be exercising.~At the beginning and at the end of each session, the participants will be asked to point out the pain they feel in the hip at that time. In each of the 8 sessions, the physiotherapist will take note of the presence, lateral pain in the hip at the beginning and end of the therapy (by VAS), number of repetitions performed in each exercise (for the group that will do core exercises, it will be noted the time in seconds of each exercise) and any adverse events. Each series of exercises will be repeated 3 times, all performed bilaterally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: There will be 2 reevaluations of the participants, similar to the initial: at the end of the exercise protocol and in a follow-up of 12 weeks after the end of the protocol.~The contraction phase of each exercise will be 2 concentric seconds, 1 isometric second and 2 eccentric seconds, followed by 1 second of rest; there will be approximately 90 seconds of rest between each set of 10 repetitions, time the other member will be exercising.~At the beginning and at the end of each session, the participants will be asked to point out the pain they feel in the hip at that time. In each of the 8 sessions, the physiotherapist will take note of the presence, lateral pain in the hip at the beginning and end of the therapy (by VAS), number of repetitions performed in each exercise (for the group that will do core exercises, it will be noted the time in seconds of each exercise) and any adverse events. Each series of exercises will be repeated 3 times, all performed bilaterally.
Study: NCT05820347

Intervention type: DEVICE
Group type: OTHER
Intervention: Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation
Description: Estimation of inspiratory muscle pressure by an artificial intelligence algorithm integrated in the mechanical ventilator (FlexiMag, Magnamed, Brazil).
Study: NCT05619276

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard serving utensil toolkit
Description: Serving a meal using standard kitchen utensils (100% of subjects experiment with these tools first)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimsed portion-control toolkit
Description: Serving a meal using optimised, portion-control utensils (100% of subjects experiment with these tools second)
Study: NCT04713475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBGM01
Description: AAVhu68 viral vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBGM01
Description: AAVhu68 viral vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBGM01
Description: AAVhu68 viral vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBGM01
Description: AAVhu68 viral vector
Study: NCT04949412

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D
Description: serum vitamin D level

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D
Description: serum vitamin D level
Study: NCT06449976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blue light defocus and blue light filtering
Description: Subjects are asked to watch a terminal display device for 50 minutes, featuring texts and videos with different defocusing treatments. Specifically, they will start by watching text for 5 minutes, followed by 40 minutes of video, and then another 5 minutes of text, totaling a visual task duration of 50 minutes. The participants will complete a total of 4 sets of tests in a random order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blue light defocus and blue light filtering
Description: Subjects are asked to watch a terminal display device for 50 minutes, featuring texts and videos with different defocusing treatments. Specifically, they will start by watching text for 5 minutes, followed by 40 minutes of video, and then another 5 minutes of text, totaling a visual task duration of 50 minutes. The participants will complete a total of 4 sets of tests in a random order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blue light defocus and blue light filtering
Description: Subjects are asked to watch a terminal display device for 50 minutes, featuring texts and videos with different defocusing treatments. Specifically, they will start by watching text for 5 minutes, followed by 40 minutes of video, and then another 5 minutes of text, totaling a visual task duration of 50 minutes. The participants will complete a total of 4 sets of tests in a random order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blue light defocus and blue light filtering
Description: Subjects are asked to watch a terminal display device for 50 minutes, featuring texts and videos with different defocusing treatments. Specifically, they will start by watching text for 5 minutes, followed by 40 minutes of video, and then another 5 minutes of text, totaling a visual task duration of 50 minutes. The participants will complete a total of 4 sets of tests in a random order.
Study: NCT05931224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D064, D702, placebo of D660
Description: Experimental Group Subjects assigned to this group are treated with D064, D702, placebo of D660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D660, placebo of D064, placebo of D702
Description: Experimental Group Subjects assigned to this group are treated with D660, placebo of D064, placebo of D702
Study: NCT05624645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelex Upp
Description: Patients were given the Pelex Upp is a non-invasive device that is designed to guide a user through personalized pelvic floor strengthening exercises. Patients used device for four weeks to treat stress urinary incontinence
Study: NCT05326035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ05129
Description: WJ05129:Twice daily (except for single dose), 12 hours apart, fixed time is recommended
Study: NCT02434835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]KWA-0711
Study: NCT06104332

Intervention type: DEVICE
Intervention: ProRhinel EXTRA Eucalyptus spray nasal
Description: ProRhinel EXTRA Eucalyptus spray nasal: until resolution of symptoms (period of 14 days maximum) ; 2 to 3 sprays per nostril; 6 times per day maximum

Intervention type: DEVICE
Intervention: RESPIMER Enfant
Description: RESPIMER Enfant: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 4 times per day maximum
Study: NCT05528237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flocked swab paired with Roche Cobas 4800
Description: Consenting individuals will insert the sterile flocked swab into the vagina, rotate at least once, and store in the provided dry tube. The sample will be stored at ambient temperature and routed to the lab for HPV testing with Roche Cobas 4800.
Study: NCT05197504

Intervention type: DRUG
Intervention: atezolizumab plus bevacizumab
Description: 1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
Study: NCT05352828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Dose: 480 mg or 6 mg/kg Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD30.CAR-T
Description: Dose: 2 x 10e8 cells/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Dose: 30 mg/m2/day x 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Dose: 70 mg/m2/day x 3 days
Study: NCT06361199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proximod
Description: Multiple-dose to establish the safety and PK profile in both healthy subjects and patients with rheumatoid arthritis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo controlled
Study: NCT06104332

Intervention type: DEVICE
Intervention: Phytosun Aroms spray nasal MAX
Description: Phytosun Aroms spray nasal MAX: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day

Intervention type: DEVICE
Intervention: PHYSIOMER RHUME TRIPLE ACTION
Description: PHYSIOMER RHUME TRIPLE ACTION: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day

Intervention type: DEVICE
Intervention: Phytosun Aroms spray nasal decongestionnant
Description: Phytosun Aroms spray nasal decongestionnant : until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 6 times per day maximum

Intervention type: DEVICE
Intervention: ProRhinel Naturel spray nasal/ URTI
Description: ProRhinel Naturel spray nasal: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 3 to 6 times per day
Study: NCT05378620

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project Dulce + Dulce Digital
Description: Project Dulce will consist of a group diabetes self-management program consisting of a 5-week curriculum delivered by a peer educator in Tagalog. The curriculum provides new knowledge as well as skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants will learn and practice self-management skills, and help one another address family, cultural, or health system barriers to managing your diabetes. Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Tagalog.